Dhanuka Agritech Zukünftiges Wachstum
Future Kriterienprüfungen 2/6
Dhanuka Agritech wird ein jährliches Gewinn- und Umsatzwachstum von 10.5% bzw. 11.5% prognostiziert. Der Gewinn pro Aktie wird voraussichtlich wachsen um 10.2% pro Jahr. Die Eigenkapitalrendite wird in 3 Jahren voraussichtlich 17.2% betragen.
Wichtige Informationen
10.5%
Wachstumsrate der Gewinne
10.17%
EPS-Wachstumsrate
| Chemicals Gewinnwachstum | 19.4% |
| Wachstumsrate der Einnahmen | 11.5% |
| Zukünftige Eigenkapitalrendite | 17.16% |
| Analystenabdeckung | Good |
| Zuletzt aktualisiert | 21 May 2026 |
Jüngste Aktualisierungen zum künftigen Wachstum
Recent updates
Narrativ-Update • May 03
507717: Upcoming Director Appointment Will Support Future Upside Confidence
Analysts have nudged their price target on Dhanuka Agritech slightly higher, with fair value moving from ₹1,426.00 to about ₹1,439.57, citing updated assumptions around the discount rate, revenue growth, profit margins and future P/E. What's in the News A postal ballot based Special or Extraordinary Shareholders Meeting is scheduled for March 19, 2026, in India (Key Developments).Narrativ-Update • Apr 18
507717: Upcoming Governance And Earnings Dates Will Support Future Upside Confidence
Analysts have trimmed their price target on Dhanuka Agritech slightly from ₹1,438.50 to ₹1,426.00, reflecting updated assumptions around the discount rate, revenue growth, profit margin, and forward P/E. What's in the News Special or Extraordinary Shareholders Meeting scheduled via postal ballot in India on Mar 19, 2026, to consider appointing Mr. Sanjiv Goel (DIN: 03616090) as an Independent Director for a first term of 5 years (company filing).Narrativ-Update • Apr 03
507717: Upcoming Governance And Earnings Dates Will Support Upside Confidence
Analysts have kept their price target for Dhanuka Agritech steady at around ₹1,438, reflecting largely unchanged views on fair value, discount rate, revenue growth, profit margin and future P/E assumptions. What's in the News Dhanuka Agritech has scheduled a Special or Extraordinary Shareholders Meeting via postal ballot in India on March 19, 2026, to consider appointing Mr. Sanjiv Goel (DIN: 03616090) as an Independent Director for a first term of 5 years (Key Developments).Narrativ-Update • Mar 19
507717: Upcoming Meetings Will Reinforce Confidence In Sustained Upside Potential
Analysts have kept the price target for Dhanuka Agritech broadly steady at around ₹1,438, with only minor model tweaks to the discount rate and the assumed future P/E driving the small change. What's in the News A Special or Extraordinary shareholders meeting is scheduled via postal ballot in India on Mar 19, 2026, to consider appointing Mr. Sanjiv Goel (DIN: 03616090) as an independent director for a first term of 5 years (company filing).Narrativ-Update • Mar 05
507717: Upcoming Meetings Will Support Confidence In Long-Term Upside Potential
Analysts have maintained their ₹1,438.50 price target for Dhanuka Agritech and made only minor adjustments to their assumptions on discount rate, revenue growth, profit margin and future P/E. These limited changes suggest that their overall valuation framework remains broadly consistent with earlier assessments.
Neues Narrativ • Feb 21
Rural Distribution And Biostimulant Tailwinds Will Support A Stronger Long Term Outlook
Catalysts About Dhanuka Agritech Dhanuka Agritech is an Indian agrochemical company supplying crop protection and allied products to farmers across major agricultural regions in India. What are the underlying business or industry changes driving this perspective?Narrativ-Update • Feb 19
507717: Upcoming Board And Shareholder Meetings Will Support Long-Term Upside Potential
Analysts have revised their price target on Dhanuka Agritech from ₹1,571.75 to ₹1,438.50, reflecting updated assumptions around the discount rate, expected revenue growth, profit margin and future P/E multiples. What's in the News Dhanuka Agritech has scheduled a Board Meeting on Feb 05, 2026, at 13:00 Indian Standard Time to consider and approve the financial results for the quarter and nine months ended Dec 31, 2025 (Key Developments).
Neues Narrativ • Feb 06
Dahej Ramp Up Risks And Regulatory Setbacks Will Eventually Support A Stronger Business
Catalysts About Dhanuka Agritech Dhanuka Agritech is an Indian agrochemical company supplying crop protection products and related offerings to farmers across major agricultural regions. What are the underlying business or industry changes driving this perspective?Narrativ-Update • Feb 04
507717: Stable Assumptions And Upcoming Results Will Support Long-Term Upside Potential
Analysts have kept their price target for Dhanuka Agritech unchanged at ₹1,571.75, citing broadly consistent assumptions for the discount rate, revenue growth, profit margin and future P/E in their refreshed model. What's in the News Dhanuka Agritech has scheduled a board meeting on Feb 05, 2026.Narrativ-Update • Jan 21
507717: Higher Margin Outlook Will Support Long-Term Upside Potential
Analysts have trimmed their price target for Dhanuka Agritech by ₹35 to ₹1,571.75. This reflects updated views on slightly lower revenue growth assumptions, a modestly higher discount rate, and a small adjustment to future P/E expectations, partly offset by a marginally higher profit margin outlook.Narrativ-Update • Jan 06
507717: Nagpur Plant Land Purchase Will Support Long-Term Upside Potential
Analysts have kept their price target for Dhanuka Agritech unchanged at ₹1,606.75, with only minor tweaks to inputs such as the discount rate, revenue growth, profit margin, and future P/E assumptions guiding their view. What's in the News Board meeting scheduled on Oct 31, 2025 at 11:00 Indian Standard Time to review and approve financial results for the quarter and half year ended Sep 30, 2025 (company filing).Narrativ-Update • Dec 16
507717: Nagpur Formulation Plant Expansion Will Drive Long-Term Upside Potential
Analysts have nudged their fair value estimate for Dhanuka Agritech down slightly from ₹1,638 to about ₹1,607 per share, reflecting tempered revenue growth expectations, partially offset by a modestly higher projected profit margin and a slightly lower assumed future P E multiple. What's in the News Board meeting scheduled on October 31, 2025, at 11:00 IST to review financial results for the quarter and half year ended September 30, 2025 (company filing) Board to consider purchase of land in Nagpur, Maharashtra, for setting up a new formulation plant, indicating planned capacity expansion (company filing) Outcome of the October 31, 2025 board meeting expected to provide clarity on near term growth, capex, and margin trajectory (company filing) Valuation Changes The fair value estimate was reduced slightly from ₹1,638 to about ₹1,607 per share, reflecting marginally softer assumptions.Narrativ-Update • Dec 02
507717: Upcoming Nagpur Plant And Board Actions Will Fuel Long-Term Momentum
Analysts have maintained their fair value estimate for Dhanuka Agritech at ₹1,638, citing stable projections for growth and profitability despite minor adjustments in underlying assumptions. What's in the News Dhanuka Agritech will hold a Board Meeting on October 31, 2025, at 11:00 Indian Standard Time (Board Meeting announcement).Narrativ-Update • Nov 17
507717: New Formulation Plant Decision Will Drive Next Wave Of Expansion
Analysts have lowered their price target for Dhanuka Agritech from ₹1,779.88 to ₹1,638.00. This reflects tempered expectations for future revenue growth and profit margins.Narrativ-Update • Nov 03
507717: New Nagpur Plant And Higher Margins Will Drive Future Upside
Analysts have revised their price target for Dhanuka Agritech downward from ₹1,875 to ₹1,779.88. This adjustment reflects updated projections in revenue growth and profit margins, as well as a slightly reduced future valuation multiple.Narrativ-Update • Sep 05
Improved Monsoon Trends And Capacity Expansion Will Drive Agrochemicals Demand
With both the discount rate and future P/E essentially unchanged, analysts maintained Dhanuka Agritech’s fair value at ₹1875. What's in the News Board meeting scheduled to consider and approve financial results for the quarter ended 30 June, 2025.
Neues Narrativ • Feb 09
Acquiring Rights To Iprovalicarb And Triadimenol Will Open International Markets
International expansion and product innovation could boost revenue through new market entry, geographic diversification, and premium pricing for unique solutions.Gewinn- und Umsatzwachstumsprognosen
| Datum | Umsatz | Gewinne | Freier Cashflow | Bargeld aus operativen Tätigkeiten | Durchschn. Anz. Analysten |
|---|---|---|---|---|---|
| 3/31/2028 | 25,956 | 3,538 | 2,533 | 3,172 | 6 |
| 3/31/2027 | 22,991 | 3,065 | 1,969 | 2,752 | 4 |
| 3/31/2026 | 20,628 | 2,872 | 1,685 | 1,962 | N/A |
| 12/31/2025 | 19,785 | 2,650 | N/A | N/A | N/A |
| 9/30/2025 | 20,138 | 2,800 | 714 | 2,663 | N/A |
| 6/30/2025 | 20,699 | 3,036 | N/A | N/A | N/A |
| 3/31/2025 | 20,352 | 2,970 | 687 | 2,627 | N/A |
| 12/31/2024 | 19,614 | 2,805 | N/A | N/A | N/A |
| 9/30/2024 | 19,194 | 2,708 | 985 | 1,431 | N/A |
| 6/30/2024 | 18,831 | 2,550 | N/A | N/A | N/A |
| 3/31/2024 | 17,585 | 2,391 | 451 | 1,345 | N/A |
| 12/31/2023 | 17,615 | 2,454 | N/A | N/A | N/A |
| 9/30/2023 | 17,516 | 2,461 | 1,061 | 2,317 | N/A |
| 6/30/2023 | 16,766 | 2,173 | N/A | N/A | N/A |
| 3/31/2023 | 17,002 | 2,335 | 120 | 1,362 | N/A |
| 12/31/2022 | 16,473 | 2,226 | N/A | N/A | N/A |
| 9/30/2022 | 16,108 | 2,191 | -640 | 331 | N/A |
| 6/30/2022 | 15,067 | 2,094 | N/A | N/A | N/A |
| 3/31/2022 | 14,778 | 2,089 | 445 | 1,043 | N/A |
| 12/31/2021 | 14,350 | 2,031 | N/A | N/A | N/A |
| 9/30/2021 | 13,738 | 2,007 | 792 | 1,038 | N/A |
| 6/30/2021 | 13,774 | 2,074 | N/A | N/A | N/A |
| 3/31/2021 | 13,875 | 2,106 | 2,184 | 2,311 | N/A |
| 12/31/2020 | 13,395 | 2,009 | N/A | N/A | N/A |
| 9/30/2020 | 13,153 | 1,886 | 2,589 | 2,726 | N/A |
| 6/30/2020 | 12,749 | 1,785 | N/A | N/A | N/A |
| 3/31/2020 | 11,201 | 1,413 | 1,484 | 1,621 | N/A |
| 12/31/2019 | 10,852 | 1,291 | N/A | N/A | N/A |
| 9/30/2019 | 10,305 | 1,160 | N/A | 627 | N/A |
| 6/30/2019 | 10,118 | 1,111 | N/A | N/A | N/A |
| 3/31/2019 | 10,058 | 1,126 | N/A | 133 | N/A |
| 12/31/2018 | 9,982 | 1,145 | N/A | N/A | N/A |
| 9/30/2018 | 10,029 | 1,285 | N/A | N/A | N/A |
| 6/30/2018 | 9,676 | 1,262 | N/A | N/A | N/A |
| 3/31/2018 | 9,626 | 1,262 | N/A | 1,377 | N/A |
| 12/31/2017 | 9,265 | 1,201 | N/A | N/A | N/A |
| 9/30/2017 | 9,168 | 1,183 | N/A | N/A | N/A |
| 6/30/2017 | 8,812 | 1,156 | N/A | N/A | N/A |
| 3/31/2017 | 8,833 | 1,219 | N/A | 631 | N/A |
| 12/31/2016 | 8,886 | 1,237 | N/A | N/A | N/A |
| 9/30/2016 | 8,857 | 1,196 | N/A | N/A | N/A |
| 6/30/2016 | 8,469 | 1,081 | N/A | N/A | N/A |
| 3/31/2016 | 8,289 | 1,073 | N/A | 1,397 | N/A |
| 12/31/2015 | 8,116 | 1,007 | N/A | N/A | N/A |
| 9/30/2015 | 7,850 | 1,002 | N/A | N/A | N/A |
| 6/30/2015 | 7,977 | 1,042 | N/A | N/A | N/A |
Analystenprognosen zum zukünftigen Wachstum
Einkommen vs. Sparrate: 507717Das prognostizierte Gewinnwachstum (10.5% pro Jahr) liegt über der Sparquote (6.9%).
Ertrag vs. Markt: 507717Die Erträge des Unternehmens (10.5% pro Jahr) werden voraussichtlich langsamer wachsen als der Markt Indian (16.4% pro Jahr).
Hohe Wachstumserträge: 507717Die Erträge des Unternehmens werden voraussichtlich steigen, jedoch nicht deutlich.
Einnahmen vs. Markt: 507717Die Einnahmen des Unternehmens (11.5% pro Jahr) werden voraussichtlich schneller wachsen als der Markt Indian (10.8% pro Jahr).
Hohe Wachstumseinnahmen: 507717Die Einnahmen des Unternehmens (11.5% pro Jahr) werden voraussichtlich langsamer wachsen als 20% pro Jahr.
Wachstumsprognosen für den Gewinn je Aktie
Künftige Eigenkapitalrendite
Künftige Eigenkapitalrendite: 507717Die Eigenkapitalrendite des Unternehmens wird in 3 Jahren voraussichtlich niedrig sein (17.2%).
Wachstumsunternehmen entdecken
Unternehmensanalyse und Finanzdaten Status
| Daten | Zuletzt aktualisiert (UTC-Zeit) |
|---|---|
| Unternehmensanalyse | 2026/05/21 19:30 |
| Aktienkurs zum Tagesende | 2026/05/21 00:00 |
| Gewinne | 2026/03/31 |
| Jährliche Einnahmen | 2026/03/31 |
Datenquellen
Die in unserer Unternehmensanalyse verwendeten Daten stammen von S&P Global Market Intelligence LLC. Die folgenden Daten werden in unserem Analysemodell verwendet, um diesen Bericht zu erstellen. Die Daten sind normalisiert, was zu einer Verzögerung bei der Verfügbarkeit der Quelle führen kann.
| Paket | Daten | Zeitrahmen | Beispiel US-Quelle * |
|---|---|---|---|
| Finanzdaten des Unternehmens | 10 Jahre |
| |
| Konsensschätzungen der Analysten | +3 Jahre |
|
|
| Marktpreise | 30 Jahre |
| |
| Eigentümerschaft | 10 Jahre |
| |
| Verwaltung | 10 Jahre |
| |
| Wichtige Entwicklungen | 10 Jahre |
|
* Beispiel für US-Wertpapiere, für nicht-US-amerikanische Wertpapiere werden gleichwertige regulatorische Formulare und Quellen verwendet.
Sofern nicht anders angegeben, beziehen sich alle Finanzdaten auf einen Jahreszeitraum, werden aber vierteljährlich aktualisiert. Dies wird als Trailing Twelve Month (TTM) oder Last Twelve Month (LTM) Daten bezeichnet. Erfahren Sie mehr.
Analysemodell und Schneeflocke
Einzelheiten zu dem Analysemodell, mit dem dieser Bericht erstellt wurde, finden Sie auf unserer Github-Seite. Außerdem bieten wir Leitfäden zur Verwendung unserer Berichte und Tutorials auf YouTube an.
Erfahren Sie mehr über das Weltklasse-Team, das das Simply Wall St-Analysemodell entworfen und entwickelt hat.
Metriken für Industrie und Sektor
Unsere Branchen- und Sektionskennzahlen werden alle 6 Stunden von Simply Wall St berechnet. Details zu unserem Verfahren finden Sie auf Github.
Analysten-Quellen
Dhanuka Agritech Limited wird von 16 Analysten beobachtet. 6 dieser Analysten hat die Umsatz- oder Gewinnschätzungen übermittelt, die als Grundlage für unseren Bericht dienen. Die von den Analysten übermittelten Daten werden im Laufe des Tages aktualisiert.
| Analyst | Einrichtung |
|---|---|
| null null | 360 ONE Capital Market Private Limited |
| null null | Anand Rathi Shares and Stock Brokers Limited |
| null null | Antique Stockbroking Ltd. |